NEW YORK, April 1, 2016 /PRNewswire/ -- Spheryx, Inc. announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant entitled "Instrument for Analyzing Protein Aggregates". This award from the National Center for Advancing Translational Sciences of the NIH will fund the development of their patented Total Holographic CharacterizationTM for analyzing protein aggregates.
Dr. Laura Philips, President and CEO stated, "The FDA has advised in its 2014 Guidance for Industry that 'It is critical for manufacturers of therapeutic protein products to minimize protein aggregation to the extent possible', while acknowledging that the technology does not currently exist to accomplish this goal. Protein aggregation occurs in the biopharmaceutical pipeline, from development, formulation, and manufacturing to storage and point of use. This NIH SBIR grant will enable Spheryx to develop Total Holographic CharacterizationTM for monitoring protein aggregates in pharmaceutical formulation and manufacturing."
About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic CharacterizationTM of colloidal materials. The breakthrough proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, thereby offering unprecedented insights into these materials' characteristics. Applications include research and development, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs. For more information please visit the company's website at www.spheryx.solutions
Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially. These risks and uncertainties include, among others: the results, timing and costs of our studies; our ability to obtain future funding on acceptable terms; the possible impairment of, or inability to obtain intellectual property rights; and innovation by our competitors.
Laura Philips, CEO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spheryx-awarded-an-nih-sbir-grant-to-use-total-holographic-characterization-for-protein-aggregate-detection-300244618.html
SOURCE Spheryx, Inc.